Team.
We are passionate scientists who believe in the potential of mRNA.
A/Prof. Tim Mercer
Director
Tim Mercer leads a laboratory and bioinformatic research group with interests in genomics, RNA
and synthetic biology.
Dr Seth Cheetham
Scientific Lead
Dr Seth Cheetham leads innovative research programs and partnerships involving mRNA technologies and their applications in health.
Dr. Jonathan Peters
Operations Lead
Jonathan Peters brings over ten year’s experience in developing nucleic acid-based technologies and manages mRNA manufacture operations.
Emily Ariens
Downstream Processes
Emily Ariens has experience in bioprocess development and specialises in mRNA purification and formulation.
Senel Idrisoglu
Project Manager
Senel Idrisoglu has experience in accredited clinical laboratories and manages mRNA projects and client relations.
Dae Jong Han
mRNA Analytics
Dae Jong performs the rigorous analysis of BASE mRNA manufacture and quality control using industry-leading techniques.
Dr Ari Golbaz Hagh
mRNA synthesis
Ari specialises in the synthesis and purification of mRNA vaccines and therapies.
Hannah Thompkins
mRNA Scientist
Hannah optimises the stability, immunogenicity and translation of mRNA.
Yohaann Jafrani
PhD student
Yohaann Jafrani is developing innovative mRNA-based technologies to identify the determinants of cell identity.
Nissa Carrodus
Laboratory Management
Nissa is developing new mRNA therapies to target cancer.
Dr Helen Gunter
mRNA Technologies
Dr Helen Gunter leads the development of novel mRNA designs and technologies, and their clinical application in human health.
Thornwit Chavalparit
PhD student
Thornwit Chavalparit is developing new mRNA technologies to improve industrial bioprocesses.
Swati Singh
PhD student
Swati Singh is developing new mRNA technologies to improve in vivo expression of encoded therapies
Shahla Kangachar
PhD student
Shahla Asgharzadeh Kangachar is developing new mRNA technologies to improve cellular translation and stability.
Maria Victorova
Honours student
Maria Victorova is using synthetic mRNAs to program immune cells to recognise and eliminate cancer.